Literature DB >> 8307776

Immunohistochemical localization of extracellular matrix in perivillous fibrinoid of normal human term placenta.

A K Nanaev1, A P Milovanov, S P Domogatsky.   

Abstract

The extracellular matrix of perivillous fibrinoid in normal human term placenta was investigated by means of the indirect immunofluorescent technique. Polyclonal antibodies to collagen types I, III, IV, V, fibronectin, fibrinogen, laminin, entactin and heparan sulphate proteoglycan and monoclonal antibodies BC-1, IST-9 and IST-4 to human fibronectin were used. The antigens can be grouped according to their presence in fibrinoid as abundant (fibrinogen, fibronectin, heparan sulphate proteoglycan, basement membrane collagen types IV and V), absent (laminin) and variable between fibrinoids (interstitial collagen types I and III, entactin). Our results also demonstrate that fibronectin in fibrinoid originates from placental cells (presumably cytotrophoblast). Monoclonal antibodies BC-1 and IST-9 specific to tissue fibronectin do not stain neighbouring placental extracellular matrix but do bind to fibrinoids on the same sections. Work by other authors has presented evidence that fibrin actually originates from maternal blood and even makes an attempt to substitute the term "fibrinoid" for "fibrin deposition". Our data on the composition of perivillous fibrinoids and the abundance of extracellular matrix components do not support this view and suggest that fibrinoid is a more relevant term for this interesting phenomenon, which deserves further investigation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8307776     DOI: 10.1007/BF00268932

Source DB:  PubMed          Journal:  Histochemistry        ISSN: 0301-5564


  22 in total

1.  Immunofluorescent study of heterogeneity in smooth muscle cells of human fetal vessels using antibodies to myosin, desmin, and vimentin.

Authors:  A K Nanaev; V P Shirinsky; K G Birukov
Journal:  Cell Tissue Res       Date:  1991-12       Impact factor: 5.249

2.  Quantification of tissue fibronectin from terminal villi of placenta.

Authors:  B A Bray
Journal:  Biochem J       Date:  1985-03-15       Impact factor: 3.857

3.  Fibrin deposits on the syncytium of the normal human placenta: evidence of their thrombogenic origin.

Authors:  N Moe; L Jorgensen
Journal:  Acta Pathol Microbiol Scand       Date:  1968

4.  The deposits of fibrin and fibrin-like materials in the basal plate of the normal human placenta.

Authors:  N Moe
Journal:  Acta Pathol Microbiol Scand       Date:  1969

5.  Immunohistochemical localization of fibronectin in the human placentas at their different stages of maturation.

Authors:  T Yamada; M Isemura; Y Yamaguchi; H Munakata; N Hayashi; M Kyogoku
Journal:  Histochemistry       Date:  1987

6.  Perivillous fibrin deposition in the human placenta.

Authors:  H Fox
Journal:  Am J Obstet Gynecol       Date:  1967-05-15       Impact factor: 8.661

7.  Relative distribution of fibronectin and type I, III, IV, V collagens in normal and atherosclerotic intima of human arteries.

Authors:  B V Shekhonin; S P Domogatsky; G L Idelson; V E Koteliansky; V S Rukosuev
Journal:  Atherosclerosis       Date:  1987-09       Impact factor: 5.162

8.  Human placental (fetal) fibronectin: increased glycosylation and higher protease resistance than plasma fibronectin. Presence of polylactosamine glycopeptides and properties of a 44-kilodalton chymotryptic collagen-binding domain: difference from human plasma fibronectin.

Authors:  B C Zhu; S F Fisher; H Pande; J Calaycay; J E Shively; R A Laine
Journal:  J Biol Chem       Date:  1984-03-25       Impact factor: 5.157

9.  Characterization of fibronectin from fetal human plasma in comparison with adult plasma fibronectin.

Authors:  Y Yamaguchi; M Isemura; M Kosakai; A Sato; M Suzuki; M Kan; Z Yosizawa
Journal:  Biochim Biophys Acta       Date:  1984-10-09

10.  The extracellular matrix is an integrated unit: ultrastructural localization of collagen types I, III, IV, V, VI, fibronectin, and laminin in human term placenta.

Authors:  P S Amenta; S Gay; A Vaheri; A Martinez-Hernandez
Journal:  Coll Relat Res       Date:  1986-06
View more
  7 in total

1.  Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta.

Authors:  Z Y Hu; Y X Liu; K Liu; S Byrne; T Ny; Q Feng; C D Ockleford
Journal:  J Anat       Date:  1999-02       Impact factor: 2.610

2.  Extracellular matrix components of the placental extravillous trophoblast: immunocytochemistry and ultrastructural distribution.

Authors:  B Huppertz; S Kertschanska; H G Frank; G Gaus; H Funayama; P Kaufmann
Journal:  Histochem Cell Biol       Date:  1996-09       Impact factor: 4.304

3.  Increase in the relative level of type V collagen during development and ageing of the placenta.

Authors:  M Iwahashi; A Ooshima; R Nakano
Journal:  J Clin Pathol       Date:  1996-11       Impact factor: 3.411

4.  Binding of antibodies against high and low molecular weight cytokeratin proteins in the human placenta with special reference to infarcts, proliferation and differentiation processes.

Authors:  H Neudeck; S L Oei; B Stiemer; H Hopp; R Graf
Journal:  Histochem J       Date:  1997-05

5.  Physiological dilation of uteroplacental arteries in the guinea pig depends on nitric oxide synthase activity of extravillous trophoblast.

Authors:  A Nanaev; K Chwalisz; H G Frank; G Kohnen; C Hegele-Hartung; P Kaufmann
Journal:  Cell Tissue Res       Date:  1995-12       Impact factor: 5.249

6.  Anti-adhesive glycosylation of fibronectin-like molecules in human placental matrix-type fibrinoid.

Authors:  H G Frank; B Huppertz; S Kertschanska; D Blanchard; D Roelcke; P Kaufmann
Journal:  Histochem Cell Biol       Date:  1995-10       Impact factor: 4.304

7.  A 3-dimensional microfluidic platform for modeling human extravillous trophoblast invasion and toxicological screening.

Authors:  Yong Pu; Jeremy Gingrich; Almudena Veiga-Lopez
Journal:  Lab Chip       Date:  2021-02-09       Impact factor: 6.799

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.